Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671

Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life and low intersubject variability ...
November 12, 2025 08:17 ET | Source: X9, Inc.

X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis Cannulation

X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis.
November 07, 2025 16:05 ET | Source: InflaRx N.V.

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CETCompany also expects to publish third quarter 2025 financial results on the same day...
November 06, 2025 09:00 ET | Source: Vibrant Gastro

New Real-World Evidence Study Demonstrates Vibrant System’s Continuous Effectiveness and Exceptional Tolerability for Chronic Idiopathic Constipation

Austin, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro announced today the publication of new real-world evidence in Clinical and Translational Gastroenterology demonstrating the long-term...
November 06, 2025 07:35 ET | Source: Urteste S.A.

Urteste S.A. launches European multicenter clinical study of the Panuri test

Urteste S.A. launches European multicenter clinical study of the Panuri test Gdańsk, Poland – 6 November 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development...
October 22, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2...
October 06, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671...
September 30, 2025 08:45 ET | Source: Nuwellis, Inc.

Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex®

ULTRA-Peds Registry Demonstrate 92% Treatment Survival in Children with AKI Fluid Overload or Congenital Kidney Failure
September 26, 2025 11:08 ET | Source: Spherix Global Insights

Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices

EXTON, Pa., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced the latest quarterly update to its RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) service,...
September 16, 2025 11:20 ET | Source: Steadman Philippon Research Institute

NIH-Funded Study Launches at SPRI to Advance Shoulder Repair Techniques

VAIL, Colorado, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI), in collaboration with the University of Texas Health Science Center at Houston (UTHealth), has...